Stevens-Johnson Syndrome Clinical Trial
Official title:
Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples
Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal necrolysis (TEN)), generalized bullous fixed drug reactions, AGEP, DRESS, drug induced immunoglobulin A (IgA) bullous dermatosis, and erythema multiforme). In order to conduct clinical and biological research studies in drug reactions, it is necessary for the investigator's department to implement a collection of clinical data and biological samples. Hypothesis/Objective: To collect clinical data and cutaneous and biological samples for immunological, biological and genetic studies to improve knowledge about pathophysiology of drug reactions. Method: The following samples will be performed in addition to the routine practice samples: one skin punch biopsy (6mm); 43 mL of blood; blister fluid aspiration; oral and nose mucous membrane and skin eSWABs, stool samples. These samples will be stored in a dedicated biological sampling department ("Platform of biological resources"). Conclusion: The implementation of this collection should allow us to conduct pathophysiological studies about drug reactions.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01696500 -
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
|
Phase 3 | |
| Terminated |
NCT02037347 -
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02126020 -
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05520086 -
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
|
Phase 1/Phase 2 | |
| Completed |
NCT06263140 -
Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
|
||
| Available |
NCT02149732 -
Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
| Recruiting |
NCT02987257 -
NATIENS: Optimal Management and Mechanisms of SJS/TEN
|
Phase 3 | |
| Completed |
NCT02945176 -
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
|
N/A | |
| Not yet recruiting |
NCT03585946 -
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
|
||
| Recruiting |
NCT04313725 -
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
|
N/A | |
| Recruiting |
NCT03046914 -
HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction
|
N/A | |
| Completed |
NCT01488396 -
Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye
|
Phase 4 | |
| Withdrawn |
NCT01256489 -
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01122303 -
Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye
|
N/A | |
| Recruiting |
NCT05145959 -
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
|
N/A | |
| Completed |
NCT00844038 -
Stevens-Johnson Syndrome Antimicrobial
|
N/A |